Familial occurrence of febrile seizures and epilepsy in severe myoclonic epilepsy of infancy (SMEI) patients with SCN1A mutations by M. Mancardi et al.
Epilepsia, 47(10):1629–1635, 2006
Blackwell Publishing, Inc.
C© 2006 International League Against Epilepsy
Familial Occurrence of Febrile Seizures and Epilepsy
in Severe Myoclonic Epilepsy of Infancy (SMEI) Patients
with SCN1A Mutations
∗Maria Margherita Mancardi, ∗‡Pasquale Striano, §Elena Gennaro, §Francesca Madia, §Roberta
Paravidino, ∗Sara Scapolan, ‖Bernardo dalla Bernardina, ¶Enrico Bertini, ∗∗Amedeo Bianchi,
††Giuseppe Capovilla, ‖Francesca Darra, ‡‡Maurizio Elia, §§Elena Freri, ‖‖Giuseppe Gobbi,
§§Tiziana Granata, ¶¶Renzo Guerrini, ∗∗∗Chiara Pantaleoni, †††Antonia Parmeggiani,
§§§Antonino Romeo, †††Margherita Santucci, ‖‖‖Marilena Vecchi, ¶¶¶Pierangelo Veggiotti,∗∗∗∗Federico Vigevano, ††††Angela Pistorio, †Roberto Gaggero, and ∗Federico Zara
∗Laboratory of Neurogenetics, Unit of Muscular and Neurodegenerative Disease, and †Department of Child Neuropsychiatry,
Epilepsy Unit, “Institute G. Gaslini,” Genova; ‡Epilepsy Center, Federico II University, Napoli; §Laboratory of Genetics, E.O.
Ospedali Galliera, Genova; ‖Department of Child Neuropsychiatry, Policlinico G.B. Rossi, Verona; ¶Unit of Molecular Medicine,
Ospedale Pediatrico “Bambino Gesu`,” Roma; ∗∗Division of Neurology, Ospedale “S. Donato,” Arezzo; ††Department of Child
Neuropsychiatry, Ospedale “C. Poma,” Mantova; ‡‡Department of Neurology, Oasi Institute for Research on Mental Retardation
and Brain Aging, Troina; §§Division of Child Neurology, Istituto Nazionale Neurologico “C. Besta,” Milano; ‖‖Unit of Child
Neuropsychiatry, Ospedale Maggiore “C.A Pizzardi,” Bologna; ¶¶Division of Child Neurology and Psychiatry, University of Pisa
and Research Institute, IRCCS Stella Maris Foundation, Pisa; ∗∗∗Division of Developmental Neurology, Istituto Nazionale
Neurologico “C. Besta,” Milano; †††Child Neurology and Psychiatry, Department of Neurological Sciences, University of Bologna;
§§§Center for Child Epilepsy, Azienda Ospedaliera “Fatebenefratelli e Oftalmico,” Milano; ‖‖‖Department of Paediatrics,
University of Padova; ¶¶¶Division of Child Neuropsychiatry, Fondazione Istituto Neurologico “C Mondino,” University of Pavia;∗∗∗∗Neurology Division, Bambino Gesu Children’s Hospital, Roma;, and ††††Unit of Epidemiology and Statistics, Institute
“G. Gaslini,” Italy
Summary: Purpose: The role of the familial background in
severe myoclonic epilepsy of infancy (SMEI) has been tradition-
ally emphasized in literature, with 25–70% of the patients having
a family history of febrile seizures (FS) or epilepsy. We explored
the genetic background of SMEI patients carrying SCN1A mu-
tations to further shed light on the genetics of this disorder.
Methods: We analyzed the occurrence of FS and epilepsy
among first- and second-degree relatives (N = 867) of 74 SMEI
probands with SCN1A mutations (70 de novo, four inherited) and
compared data with age-matched and ethnically matched control
families. Familial clustering and syndromic concordance within
the affected relatives in both groups were investigated.
Results: The frequency of FS or epilepsy in relatives of SMEI
patients did not significantly differ from that in controls (FS: 13
of 867 vs. 12 of 674, p = 0.66; epilepsy: 15 of 867 vs. six of 674,
p = 0.16). Different forms of epilepsy were identified in both
relatives of SMEI probands and controls. Twenty-eight relatives
with FS and epilepsy were distributed in 20 (27%) of 74 SMEI
families; among the controls, 18 affected relatives were clus-
tered in 13 (18.5%) of 70 families. No pedigree showed several
affected members, including the four with inherited mutations.
Conclusions: A substantial epileptic family background is not
present in our SMEI patients with SCN1A mutations. These data
do not confirm previous observations and would not support
polygenic inheritance in SMEI. The investigation of the family
background in additional series of SMEI patients will further
shed light on the genetics of this syndrome. Key Words: Severe
myoclonic epilepsy of infancy—Voltage-gated sodium channel
αsubunit type A—Genetics.
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Severe myoclonic epilepsy of infancy (SMEI) is an
intractable epileptic encephalopathy typically beginning
during the first year of life with febrile or afebrile hemi-
clonic or generalized prolonged seizures. Subsequently,
other seizure types occur, including myoclonic, par-
tial, and absence seizures. Photosensitivity is common.
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Psychomotor-development stagnation begins around the
second year of life (Dravet et al., 2005). Ataxia, pyra-
midal signs, and interictal myoclonus can also appear.
According to the International League Against Epilepsy
(ILAE) classification, SMEI is defined as “syndrome
undetermined as to whether it is focal or generalized”
(Commission on Classification and Terminology of the In-
ternational League Against Epilepsy, 1989) because both
generalized and focal seizure types occur. SMEI is usually
a sporadic condition and familial cases are rarely reported
(Singh et al., 2001; Dravet et al., 2005). SMEI has often
been associated with a family history of seizure disorders
(Dravet et al., 2005), but only one study specifically ad-
dressed this issue and found an increased frequency of
febrile seizures (FS) and epilepsy in relatives of SMEI
patients (Benlounis et al., 2001).
In recent years, heterozygous de novo mutations in the
α-subunit type A of the voltage-gated sodium channel
gene (SCN1A) have been reported in patients with SMEI
(Claes et al., 2001), suggesting a monogenic nature for this
disorder. However, the recurrence of epilepsy and FSs in
SMEI families and the identification of SCN1A mutations
in parents with mild epileptic phenotypes (Gennaro et al.,
2003; Nabbout et al., 2003; Fukuma et al., 2004; Kimura
et al., 2005) led to the hypothesis that additional inherited
genetic factors could influence the familial epileptic back-
ground and modulate the expression of SCN1A mutations
(Fujiwara et al., 2003). In this scenario, SMEI would be
an oligogenic disorder caused by the association of a ma-
jor player—SCN1A—with one or more additional genetic
partners.
In this study, we investigated familial antecedents of FSs
and epilepsy in 74 SMEI patients with SCN1A mutations to
explore the genetic background of a homogeneous group
of SMEI patients and to shed light on the genetics of this
disorder.
METHODS
Inclusion criteria
Patients
Diagnosis of SMEI was made according to the follow-
ing criteria: (a) no history of acquired brain injury, (b)
normal cognitive and motor development before seizure
onset, (c) onset of febrile or afebrile seizures, general-
ized or unilateral, before age 1 year, (d) myoclonic jerks,
(e) intractable epilepsy, and (f) psychomotor delay within
2 years from seizure onset. For the purposes of this
study, we selected SMEI patients referred from 15 Ital-
ian Epilepsy Centers and showing SCN1A mutation.
Probands were selected blind to familial antecedents.
Controls
Among subjects admitted to Gaslini Institute, Genova,
for acute traumatic or infectious events, we selected 70
subjects (43 boys, 27 girls) with no evidence of neuro-
logic disease and matched for sex and age with the SMEI
group.
Genetic analysis
Genomic DNA was extracted from peripheral blood
according to standard methods. SCN1A exons were am-
plified by polymerase chain reaction (PCR) in 29 frag-
ments from genomic DNA of each patient. PCR fragments
were then analyzed by denaturing high-performance liq-
uid chromatography on the WAVE automated instrument
(Transgenomic Inc., Omaha, NE, U.S.A.). Fragments
showing an abnormal chromatogram compared with con-
trol were subsequently sequenced (Nabbout et al., 2003).
For each SMEI proband, possible hereditary transmission
of mutations was excluded by testing parents’ DNA.
Genealogic documentation and clinical evaluation of
relatives
Detailed pedigrees extending to second-degree relatives
were constructed for SMEI probands and controls. Infor-
mation was collected from parents or relatives through
semistructured interviews. Clinical and instrumental data
of the affected family members were analyzed to deter-
mine the type and etiology of seizures. Epileptic seizures
and syndromes were classified according the ILAE cri-
teria (Commission on Classification and Terminology of
the International League Against Epilepsy, 1981, 1989).
“Febrile seizure plus” (FS+) indicated recurrent FS ex-
tending beyond 6 years, or with afebrile generalized tonic–
clonic seizures (GTCS) (Singh et al., 1999; Singh et al.,
2001). The term “unclassified seizures” was used when
data were insufficient to diagnose a specific seizure type
or epilepsy syndrome.
Statistical analysis
Descriptive statistics of qualitative data were performed
and reported in terms of absolute frequencies. The com-
parison of qualitative data between groups of subjects was
made by means of the χ2 test, or the Fisher’s exact test
in case of expected frequencies less than five. Subgroup
analyses have been performed for first- and second-degree
relatives in both SMEI patients and controls. The Bonfer-
roni correction was applied for all the subgroups analyses
(pB). All the tests were two-sided, and a p value < 0.05
was considered statistically significant.
Sample power estimates were calculated according to
the method described by Fleiss et al (1980), assuming an
α error of 0.05, a β error of 0.2 (i.e., a power of 80%).
Considering an estimated relative frequency of FS in the
control group of 0.02, the minimum number of subjects
needed to detect a difference ≥0.03 is equal to 653, for
each group. Considering an estimated relative frequency
of epilepsy in the control group of 0.01, the minimum
number of subjects needed to detect a difference ≥0.02 is
equal to 866, for each group.
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The statistical package Stata release 7 (Stata Corpo-
ration, college Station, TX, U.S.A.) was used for all the
analyses, and the package NQuery Advisor release 5.0,
for the sample-size estimation.
RESULTS
Epileptology of probands
The study included 74 consecutive SMEI patients (38
boys, 36 girls) with SCN1A mutation. Age at first seizure
was 3–12 months (mean, 5.4 months). Initial seizures were
FSs in 49 cases, afebrile tonic or clonic or tonic–clonic in
25. All probands showed an intractable epilepsy and dif-
ferent type of seizures. During follow-up, all the probands
experienced at least one generalized seizure; 42 had ab-
sence seizures, 58 had unilateral motor seizures, and 56
had other types of partial seizures, mainly complex par-
tial. Between 1 and 4 years of life, all subjects manifested
segmental or massive myoclonic jerks. Status epilepticus
occurred in 48 cases, whereas almost half of the patients
showed ataxia.
Genetic findings
The list of SCN1A mutations identified in SMEI pa-
tients is reported in Table 1. Seventy mutations occurred
de novo, whereas four were inherited from the mother.
Twenty-four mutations, including the four inherited, have
been previously published (Nabbout et al., 2003; Gennaro
et al., 2006). Twenty-seven (36.4%) SMEI probands
showed SCN1A missense mutations. Truncating muta-
tions (nonsense and frameshift) occurred in 38 subjects
(51.3%), whereas mutations affecting the splice sites were
found in nine (12.2%).
Familial occurrence of febrile seizures and epilepsy
A total of 214 first-degree (108 male, 106 female) and
653 second-degree (308 male, 345 female) relatives (total,
867) of SMEI probands were ascertained. Control group
included 184 first-degree (97 male, 87 female) and 490
second-degree (241 male, 249 female) relatives (n = 674).
None of the pedigrees showed evidence of consanguinity.
Affected relatives of SMEI probands and controls are re-
ported in Table 2.
Febrile seizures in relatives
Among relatives of SMEI probands, 13 (eight female,
five male) out of 867 (1.5%) individuals had single (nine
cases) or multiple (four cases) of FS. No subject expe-
rienced isolated FS+. Within the control group, 12 (four
females, eight males) relatives of 674 (1.8%) had single
(10 cases) or multiple (two cases) of FS.
No significant difference (p = 0.74) was found be-
tween first-degree (four of 184) and second-degree rel-
atives (eight of 490) of controls, indicating that the age
of relatives did not bias the ascertainment of FS. Overall,
the frequency of FS in relatives of SMEI patients did not
significantly differ from that in controls (13 of 867 vs. 12
TABLE 1. SCN1A mutations in 74 patients with SMEI
MutationFamily
ID DNA Protein Inheritance Type
1 c.969 T>A Y323X De novo Premature
truncation
2 c.1165C>T Q389X De novo Premature
truncation
3 c.3697G>C G1233R De novo Missense
4 c.5008-
5011delTGTT
F1671fsX1679 De novo Premature
truncation
5 c.5674C>T R1892X De novo Premature
truncation
6 c.4388T>C F1463S De novo Missense
7 c.680T>G I227S De novo Missense
8 c.5285G>A G1762E De novo Missense
9 IVS2+3T>G N/A De novo Splicing
10 c.5141T>G M1714R De novo Missense
11 c865G>C E289X Maternal Premature
truncation
12 c.5656C>T R1886X De novo Premature
truncation
13 c.249C>G Y83X De novo Premature
truncation
14 c.853-
856delCTTC
A285fsX290 De novo Premature
truncation
15 c.234G>T E78D De novo Missense
16 c.664C>T R222X De novo Premature
truncation
17 iIVS24+2A>G N/A De novo Splicing
18 c.4486delG Q1496fsX1500 De novo Premature
truncation
19 c.680T>G I227S De novo Missense
20 c.2435C>G T808R De novo Missense
21 c.1624C>T R542X De novo Premature
truncation
22 iIVS4+1C>T N/A De novo Splicing
23 c.4542C>A S1516X De novo Premature
truncation
24 c.3295 G>T E1099X De novo Premature
truncation
25 c890C>T c890C>T Maternal Missense
26 del3867-3869
CTT
delF1298 De novo Premature
truncation
27 IVS1+5 G>A N/A De novo Splicing
28 c.2678T>A L893X De novo Premature
truncation
29 c.838T>C W280R De novo Missense
30 c.4277T>G L1426R De novo Missense
31 c.1129C>T R377X De novo Premature
truncation
32 c.664C>T R222X De novo Premature
truncation
33 c.2536G>A E853K De novo Missense
34 c.992insT L331fsX339 De novo Premature
truncation
35 del c.3997-4002 M1333X De novo Premature
truncation
36 c.1177T>C R393C De novo Missense
37 c.484A>C T162P De novo Missense
38 c.5339T>C M1780T De novo Missense
39 c5002C>G P1668A Maternal Missense
40 c.3173delAAGA K1058fs1079X De novo Premature
truncation
41 c.4352C>T P1451L De novo Missense
42 c.277-278delTT N94X De novo Stop
43 c.3733C>T R1245X De novo Stop
44 c.1177C>A R393S De novo Missense
45 c5240insAA 1747Nfs1779X Maternal Premature
truncation
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TABLE 1. Continued.
MutationFamily
ID DNA Protein Inheritance Type
46 c.5414-5415delTT F1805X De novo Stop
47 c.5040insAA M1681fsX1715 De novo Stop
48 del c.2916-2919 T970fsX972 De novo Stop
49 IVS10+1G>T N/A De novo Splicing
50 c.1276T>A Y426N De novo Missense
51 c.1121delC S374fsX378 De novo Stop
52 c.5674C>T R1892X De novo Stop
53 c.3733C>T R1245X De novo Stop
54 IVS18+1G>T N/A De novo Splicing
55 del c.3696G ins22 L1235fsX1243 De novo Stop
56 c.5318C>T S1773F De novo Missense
57 c.664C>T R222X De novo Stop
58 c.5531delCAAA N1845fsX1856 De novo Stop
59 c.650C>A T217K De novo Missense
60 c.2825T/C L942P De novo Missense
61 c.4424T>C L1475S De novo Missense
62 del c.387-389
ATT
delL129 De novo Stop
63 c.1837C>T R613X De novo Stop
64 c.1149C>G F383D De novo Missense
65 c.5668delG E1890fsX1910 De novo Stop
66 c.383C>A S128X De novo Stop
67 c.5657delG R1886fsX1910 De novo Stop
68 c.3734G>A R1245Q De novo Missense
69 IVS18-1G>A N/A De novo Splicing
70 c.580G>A D194N De novo Missense
71 c.4265A>G Y1422C De novo Missense
72 IVS25-1G>C N/A De novo Splicing
73 IVS5+1G>C N/A De novo Splicing
74 c.1042G>T G348X De novo Stop
of 674; p = 0.66). Stratification analysis indicate that the
frequency of FS was not significantly increased in either
first-degree (three of 214 vs. four of 184; pB = 0.98) or
second-degree relatives (10 of 653 vs. eight of 490; pB =
1.00) compared with controls.
TABLE 2. Occurrence of febrile seizures and epilepsy among relatives of SMEI probands and controls
Familial antecedents
SMEI Controls
First degree (n = 214) Second First degree (n = 184) Seconddegree Total degree Total
Seizure type Mother Father Sibs (n = 653) (n = 867) Mother Father Sibs (n = 490) (n = 674)
Febrile seizures 1a 1 1 10 13 1 2 1 8 12
Idiopathic generalized epilepsy 6 1
CAE - - - 1 1 - - - - 0
GTCS 2 1 - 1 4 1 - - - 1
FS+ - - - 1 1 - - - - 0
Idiopathic partial epilepsy 3 0
BECTS - 1 - 2 3 - - - - 0
SMEI - - 2a - 2 - - - - 0
Cryptogenic epilepsy - - - - - - - - 1 1
Symptomatic epilepsy - - - 1 1 - - 1 3 4
Undetermined seizures 1a - - 2 3 - - - - 0
CAE, childhood absence epilepsy; GTCS, generalized tonic–clonic seizure; FS+, febrile seizures plus; BECTS, benign epilepsy with centrotemporal
spikes.
aRelatives carrying SCN1A mutations.
Epilepsy in relatives
Among SMEI relatives,15 (10 female, five male)
of 867 (1.7%) individuals had a history of epilepsy
(Table 2). Within the control group, epilepsy was found in
six of 674 (0.9%) relatives without a significant difference
between first- and second-degree relatives (two of 184 vs.
four of 490; p = 0.67).
The frequency of epilepsy in relatives of SMEI was not
significantly increased compared with controls (15 of 867
vs. six of 674; p = 0.16).
Epilepsy phenotypes in relatives of SMEI patients and
controls were the following:
• Idiopathic generalized epilepsy: four SMEI rela-
tives were affected by epilepsy with GTCSs. One
had FS+. Childhood absence epilepsy (CAE) oc-
curred in one SMEI relative. One subject from the
control group had epilepsy with GTCS;
• Idiopathic partial epilepsy: three SMEI relatives
had typical benign epilepsy with centrotemporal
spikes (BECTS);
• SMEI: two siblings carrying inherited mutations
were affected by SMEI;
• Cryptogenic epilepsy: one individual belonging to
the control group was affected by temporal lobe
epilepsy (TLE) with onset at age 52 years;
• Symptomatic epilepsy: one SMEI relative had
seizures due to perinatal hypoxic–ischemic en-
cephalopathy. In the control group, one subject had
mesial temporal sclerosis with TLE; three individ-
uals were affected by epilepsy due to perinatal hy-
poxic ischemic damage (n = 2) and stroke sequelae
(n = 1);
• Undetermined seizures: two SMEI relatives, belon-
ging to the same family, had rare, drug-responsive
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FIG. 1. Pedigrees of SMEI probands with de novo SCN1A mutations (A) and control subjects (B), showing two or more affected relatives.
seizures diagnosed as absences, during the
menopausal age. A mother bearing a truncating
mutation experienced focal seizures during early
adolescence (Nabbout et al., 2003). However, as
no EEG was available, we considered these cases
affected by undetermined seizures.
Idiopathic generalized epilepsy occurred more fre-
quently in relatives of SMEI probands (six of 867) than
in controls (one of 674), but this difference is not statis-
tically significant (pB = 0.47). The frequency of epilepsy
was not increased in either first-degree relatives of SMEI
probands (seven of 214 vs. two of 184; pB = 0.99) or
second-degree relatives (eight of 653 vs. four of 490;
pB = 0.94) compared with controls.
Familial clustering
Twenty-eight relatives with FSs and epilepsy were dis-
tributed in 20 (27%) of 74 SMEI families: 13 (17.6%)
showed a single additional affected relative (six with FSs,
seven with epilepsy), six (8.1%) had two additional af-
fected relatives, and one (1.3%) showed three additional
affected members. Among SMEI families with multi-
ple affected members, four showed clinical heterogeneity
(Fig. 1A): families 4 and 65 had two relatives with FSs
and BECTS; family 43 had two subjects with FSs and one
with IGE and FS+. In family 24 and family 74, relatives
were concordant for FS and IGE, respectively (Fig. 1A).
Family 10 showed two relatives affected by epilepsy of un-
determined type. In family 45, the mother had a single FS
during infancy, and the proband’s brother was affected by
SMEI. Recently we demonstrated that the mutation was
inherited by the affected siblings from the mother who
showed a somatic mosaicism (Gennaro et al., 2006).
Within the control group, 18 affected relatives were
clustered in 13 (18.6%) of 70 families: eight (11.4%) fam-
ilies showed one affected subject, and five (7.1%) showed
two affected subjects (Fig. 1B). None of the SMEI or con-
trol families showed a history of seizures in both the pa-
ternal and maternal branches.
DISCUSSION
The role of the family background in SMEI has been tra-
ditionally emphasized in the literature. It was reported by
different studies that 25–70% of SMEI patients have a pos-
itive family history of FSs or epilepsy (Singh et al., 2001;
Nabbout et al., 2003; Scheffer et al., 2003; Dravet et al.,
2005). However, only Benlounis et al. (2001) approached
this issue methodically and found that the frequency of
FSs and epilepsy was significantly increased in relatives of
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FIG. 2. Pedigrees of SMEI probands with inherited SCN1A mutations. +, wild-type allele; −, SCN1A mutation.
SMEI patients compared with a control group. As epilepsy
in relatives had the characteristics of idiopathic general-
ized epilepsy (IGE), the authors concluded that SMEI is
genetically linked to FS and to other phenotypes of IGE.
The identification of de novo SCN1A mutations in SMEI
probands and the lack of SCN1A mutations in families
with common forms of IGE (Escayg et al., 2001) or FS
(Malacarne et al., 2002) challenged this view and sug-
gested our investigation of the familial antecedents of FS
and epilepsy in a homogeneous group of SMEI patients
showing SCN1A mutations.
In our series, 27% of SMEI probands characterized by
SCN1A mutations have a family history of seizures. How-
ever, because of the high frequency of FS (2–5%) and
epilepsy (∼0.5–1%) in the general population (Hauser et
al., 1991), this finding is not indicative by itself of an in-
creased risk for relatives of SMEI probands. We found
that FS and epilepsy occur in 18.5% of age-matched and
ethnically matched control families. Moreover, system-
atic analysis of first- and second-degree relatives of SMEI
probands and controls demonstrated that the frequency
of FS and epilepsy was not significantly increased in our
series of SMEI families carrying SCN1A mutations.
Power estimates, calculated on the actual frequency of
FS in the control population, indicate that the available
sample can detect a ≥2.5-fold increase frequency of FS
among SMEI relatives. Because of the lower frequency
of epilepsy with respect to FS, the available sample can
detect a ≥3-fold increased frequency of epilepsy among
SMEI relatives. Minor differences (e.g., twofold) in FS
and epilepsy frequencies between relatives of SMEI pa-
tients and the general population cannot be detected by
our study and would require a sample size on the order of
thousands.
Our findings are in contrast with the study of Benlounis
et al. (2001). The criteria of selection of SMEI population
could be responsible of conflicting findings. In Benlou-
nis et al. (2001), the SMEI sample was selected blind to
molecular analysis, and it is likely to be genetically het-
erogeneous, as a proportion of SMEI patients do not carry
SCN1A mutations (Mulley et al., 2005). The family back-
ground of SMEI patients without SCN1A mutations—who
were not included in our study—may differ from that of
patients bearing SCN1A mutations. The characteristics of
the control population could also have affected statisti-
cal outcomes. In Benlounis et al. (2001) control families
showed a very low frequency of FS (1 of 222; < 0.5%)
and no family members with epilepsy. Conversely, in the
present study, the frequency of FS and epilepsy among
relatives of controls was similar to that observed in gen-
eral population (Hauser et al., 1991), with a homogeneous
distribution among first- and second-degree relatives of
controls.
It has been reported that FS+ and IGE are the more
frequent epileptic phenotypes among relatives of SMEI
probands (Benlounis et al., 2001; Singh et al., 2001).
In the present study, different forms of epilepsy were
identified in both relatives of SMEI probands and controls.
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IGEs occurred more frequently in the SMEI group, but the
difference is not statistically significant.
The analysis of familial clustering failed to identify
pedigrees with several affected members. The majority
(13 of 20, 65%) of SMEI pedigrees with a family his-
tory showed a single relative affected by FS or epilepsy.
Moreover, families with multiple affected relatives were
equally frequent in SMEI and control groups (9.5% vs.
7.1%).
Interestingly, the four families segregating SCN1A
mutations have no second-degree members affected by
epilepsy or FS and do not show a significant familial clus-
tering. Accordingly, in these families, none of the second-
degree relatives carries a SCN1A mutation. Furthermore,
we showed that the mutation occurred de novo in the
proband’s mother in two instances (SMEI 11, SMEI 45;
Fig. 2).
The family history for FS and epilepsy previously re-
ported in different clinical series as well as the variable
expressivity of SCN1A mutations in parents of SMEI
probands suggest that mutations in SCN1A could not be
the only genetic player in the etiology of SMEI (Scheffer
et al., 2003; Mulley et al., 2005).
However, in this study, we showed that a substantial
epileptic family background is not present in 74 SMEI
patients with SCN1A mutations. In addition, the four fam-
ilies with inherited mutations do not show several affected
members, probably because of the de novo origin of the
mutations in the parents. These data and our recent obser-
vation that somatic mosaicism may account for variable
expressivity of SCN1A mutations in SMEI families would
suggest that SMEI is a monogenic rather than a multifac-
torial condition (Gennaro et al., 2006). The investigation
of the family background and the detection of somatic mo-
saicism in additional series of SMEI patients will further
shed light on the genetics of this syndrome.
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